A racing heart post‐Pfizer/
Journal of Arrhythmia, 2022 Palpitations is one of the most common side effects experienced post-messenger-RNA COVID-19 vaccines. However, some patients experience significant symptoms and further workup needs to be considered. We present an interesting case of inappropriate sinus tachycardia in a fit gentleman who presented with worsening palpitations and elevated heart rate ...
Hooi Khee Teo +4 more
openaire +3 more sources
Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines:international network cohort study from five European countries and the US [PDF]
, 2022 OBJECTIVE: To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with use of adenovirus based covid-19 vaccines versus mRNA based covid-19 vaccines.
Burn, Edward +16 more
core +2 more sources
Safety and BNT162b2 mRNA COVID-19 vaccination.
Acta bio-medica : Atenei Parmensis, 2021 n/a.
Joob, Beuy, Wiwanitkit, Viroj
openaire +2 more sources
Human Vaccines & Immunotherapeutics, 2023 The mRNA-based BNT162b2 and inactivated whole-virus CoronaVac are two widely used COVID-19 vaccines that confer immune protection to healthy individuals. However, hesitancy toward COVID-19 vaccination appeared to be common for patients with neuromuscular
Michael Kwan Leung Yu +9 more
doaj +1 more source
COVID-19 vaccine in the Kingdom of Saudi Arabia: A true operation warp speed
Journal of Nature and Science of Medicine, 2021 As of January 2021, 1 year has passed since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first discovered, which is the cause of the coronavirus disease-2019 (COVID-19) pandemic that has infected almost 100 million people ...
Mazin Barry, Ahmed S BaHammam
doaj +1 more source
Extended interval BNT162b2 vaccination enhances peak antibody generation [PDF]
npj Vaccines, 2022 Abstract The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies 1 . However, many countries extended this interval to accelerate population coverage with a single vaccine.
Helen Parry +9 more
openaire +3 more sources
Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort [PDF]
, 2023 Thrombosis associated with thrombocytopenia was a matter of concern post first and second doses of BNT162b2 and ChAdOx1 COVID-19 vaccines. Therefore, it is important to investigate the risk of thrombocytopenic, thromboembolic and haemorrhagic events ...
Agrawal, U +15 more
core +5 more sources
BNT162b2 mRNA COVID-19 Vaccine: First Approval [PDF]
Drugs, 2021 BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
openaire +2 more sources
Evaluation of the effectiveness of BNT162b2 primary vaccination and booster dose to SARS-CoV-2 in eliciting stable mucosal immunity [PDF]
, 2022 The waning effectiveness of the primary vaccination for SARS-CoV-2 led to administration of an additional booster dose (BD). The efficacy of the BD in stimulating humoral systemic immune response is well established, but its effectiveness on inducing ...
Angeloni A. +6 more
core +1 more source
Myopericarditis following both BNT162b2 and NVX-CoV2373
Allergy, Asthma & Clinical Immunology, 2022 Abstract Background Myopericarditis is a well reported complication associated with SARS-Cov-2 (COVID-19) infection and vaccinations; particularly with mRNA vaccines (BNT162b2 and mRNA-1273), and in the young male population.
Saima Ahmad +3 more
openaire +3 more sources